Search
Despite the promise of eventually using artificial intelligence to detect melanoma, much more research and development are needed, MSK experts find.
Cancer DNA taken from spinal fluid could serve as a liquid biopsy that provides information on brain tumor mutations.
A leader in developing better treatments for a range of blood cancers, Dr. Omar Abdel-Wahab is only the second person from MSK to receive the Paul Marks Prize for Cancer Research.
Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August.
Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.
Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).
Get to know Ashley Chui, a chemical biology graduate student in the Sloan Kettering Institute.
Joan Argetsinger Steitz, PhD, Sterling Professor of Molecular Biophysics and Biochemistry at Yale School of Medicine, will also be honored with the 2021 Honorary Degree and the MSK Medal for Outstanding Contributions to Biomedical Research.
A low-dose radiation approach could help more patients avoid side effects of treatment for head and neck cancer.
Several MSK physicians and researchers presenting during the plenary sessions.